Functional signatures predict risk of clinically significant CMV independent of T-cell depletion. (A) The 100-day cumulative incidence of clinically significant CMV by administration of ATG during conditioning regimen. (B) The 100-day cumulative incidence of clinically significant CMV by administration of ATG and levels of the NPS (IL-2⁻IFN-γ⁺TNF-α⁻MIP-1β⁺ cells within the CMV(pp65)-specific CD8⁺ T-cell compartment) using 16% as cutoff is shown. Immunophenotyping was performed on day +30. Note that even though administration of ATG confers significant risk of CMV (A), the risk among ATG-treated patients is higher or lower depending on the levels of the NPS (B). P values correspond to the log-rank test. P value in panel B is for the comparison between ATG_yes NPS_low and ATG_yes NPS_high groups; the P value for overall differences between the 4 groups was P = .001. The number of patients at risk was as follows: 34 and 22 for ATG vs no ATG, respectively, in panel A; and 12, 9, 7, and 8 for ATG_no NPS_low, ATG_no NPS_high, ATG_yes NPS_low, and ATG_yes NPS_high, respectively.